New analyses of clinical data from Alpha1H treated patients with bladder cancer detect a strong immune response with known anti-tumor effects
Hamlet BioPharma’s drug candidate Alpha1H has been shown to affect a majority of tumors in treated patients with cancer of the urinary bladder. A new analysis now provides a further explanation for this strong effect, based on an immune response in the treated patients with known anti-tumor effects. Thus, in addition to killing tumor cells and inducing tumor cell shedding, Alpha1H activates a broad immune response, which adds a strong protective potential against cancer. The manuscript for this study has been submitted for publication. Alpha1H complex kills several types of cancer